PK 051
Alternative Names: PK-051Latest Information Update: 17 Nov 2023
At a glance
- Originator PharmaKure
- Class Antidementias; Antidepressants; Antipsychotics; Behavioural disorder therapies; Neuroprotectants
- Mechanism of Action Amyloid beta-protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Alzheimer's disease
Most Recent Events
- 22 Sep 2023 Phase-II clinical trials in Alzheimer's disease in USA, prior to September 2023 (PO) (PharmaKure pipeline, September 2023)
- 31 Jan 2023 PharmaKure announces intention to submit CTA to UK MHRA for Alzheimer's disease in March 2023
- 02 Feb 2013 PharmaKure has patent protection for treatment of protein aggregation diseases by combination of two active medicaments in USA